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ABSTRACT 
Background: Operative hysteroscopy has gained popularity as a minimally invasive 
approach in the management of intrauterine abnormalities.  Cervical dilatation represents a 
real challenge during the procedure.  Misoprostol, a synthetic prostaglandin E1 analogue has 
a cervical ripening effect in both pregnant and non-pregnant patients.  
Objectives: To investigate vaginal misoprostol in facilitating cervical dilatation prior to 
operative hysteroscopy.   
Material and Methods: This was an open controlled clinical trial conducted at Misurata, 
Libya. Patients were randomized into two groups of (60 each): misoprostol group received 
400 μg misoprostol (cytotec), self-administered vaginally 3-4 hrs prior to the operation 
(hysteroscopy) and control group received no treatment.   
Results: The two groups were well matched in their age, parity, presentations and indications 
of the procedure. Compared with the controls, significantly more cervical dilatation was 
achieved in significantly shorter time in misoprostol group. Likewise the duration of the 
operative hysteroscopy was also significantly shorter in the misoprostol group. Significantly 
fewer patients in misoprostol group had cervical lacerations, creation of false passage during 
cervical dilatation and uterine perforations.    
Conclusion: In summary, the study showed that vaginal misoprostol administered 3-4 hour 
before operative hysteroscopy reduce the need for cervical dilatation and facilitate 
hysteroscopic surgery. 
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perative hysteroscopy is popular 
minimally invasive approach in the 
management of intrauterine lesions 
such as endometrial polyps; submucous 
fibroid, intrauterine adhesions, and uterine 
septum1. Insertion of hysteroscopic 
resectoscope usually requires a dilatation 
of the cervix.  Achieving this degree of 
dilatation in the non-gravid cervix is 
difficult and  might  be impossible without  
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prior cervical ripening.Therefore 
complications (cervical  tear, creation  of  
false  passage, and uterine perforation) 
might encounter during the procedure of 
the insertion of the hysteroscopy or to the 
dilatation of the cervical canal2-4. 
Furthermore, some hysteroscopic 
operations such as myomectomy need 
longer duration for adequate cervical 
dilatation to facilitate repeated insertions 
and withdrawals of the resectoscope to 
allow complete extraction of the excised 
lesions.  Thus an efficient method to 
facilitate an easier uncomplicated entry 
through ripened cervix during 
hysteroscopic procedure could 
substantially minimize the risk of 
complications.   Application of 
O
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intracervical sulprostone gel before 
diagnostic hysteroscopy yield a significant 
reduction in the force required to dilate the 
cervix5. Likewise, the vaginal use of 
metenoprost potassium before outpatient 
hysteroscopy in infertile patients provided 
sufficient dilatation of the cervical canal to 
permit the insertion of a hysteroscope 
without additional mechanical dilatation6. 
Preoperative cervical ripening may be 
achieved other method e.g. osmotic dilator 
(Laminaria) and misoprostol7-12. 
Misoprostol, a synthetic prostaglandin E1 
analogue was found to be successfully 
ripen the cervix either when give for 
medical abortion during first or second 
trimester13, or when used for labor 
induction14. Consequently, given its high 
efficacy in dilating the cervix also 
facilitate dilatation in women undergoing 
hysteroscopy5-17. The total systemic 
bioavailability of vaginally administered 
misoprostol was three times greater than 
that of orally administered misoprostol18, 
and might explain why vaginal 
misoprostol is more effective than oral 
misoprostol when used medical abortion 
and before hysteroscopy15, 19. Yet, other 
studies showed that all routes, oral, 
sublingual administration, vaginal, 
intracervical before hysteroscopy were 
equally effective in ripening the cervix9,17, 
20. 
In addition, the primary advantages of 
misoprostol were cheaper price, can be 
kept at room temperature, greater 
acceptability by doctors and patients21. 
There are few published data on the use of 
misoprostol in ripening the cervix before 
hysteroscopy and most of these are from  
developed world. The current study was 
conducted to investigate the use of vaginal 
misoprostol before operative hysteroscopy. 
MATERIALS AND METHODS: 
An opened controlled clinical trial was 
carried out during the period of October 
2012 to September 2013 at the 
Gynecology Department of Misurata 
Hospital.  It was approved by the Medical 
Ethics Committee of the Hospital.  After 
signing an informed consent, symptomatic 
patients and suspected to have intrauterine 
pathology, such as a submucous myoma, 
endometrial polyps or other endometrial 
pathological findings based on the 
transvaginal ultrasound, were enrolled.   
The study comprised women with different 
indications for operative hysteroscopy. 
The obstetric history was gathered using 
questionnaires and pelvic examinations 
with transvaginal ultrasonography was 
performed to determine the nature, site and 
extent of intrauterine lesions.  Those with 
genital infection, history of cervical 
surgery, endometrial lesions with 
suspected endo- or ecto-cervical lesions 
that could affect the cervical resistance, or 
patients that were not candidates for 
surgery were excluded.  Patients were 
randomized into two groups using 
computer generated numbers and sealed 
envelopes.  The misoprostol group 
received 400 g misoprostol (self-
administered) vaginally 3-4 hours before 
operative hysteroscopy and the control 
group who received no treatment before 
hysteroscopy. 
All the hysteroscopic surgeries were 
performed in the early proliferative phase 
of the menstrual cycle with a Carl Storz 9-
mm hysteroscope under general 
anaesthesia.  In the operating room, the 
degree of initial cervical dilatation was 
assessed by introducing Hegar dilators 
under general anesthesia.  It was defined as 
the maximal caliber dilator that passed 
without resistance in   ascending   manner   
starting  with   Hegar   
size 4.  The primary outcome measure was 
number of patients achieving a pre-
operative cervical dilatation of 7mm.  The 
secondary outcome measures included the 
subjective ease of cervical dilatation; the 
time required for dilatation up to Hegar 10, 
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time required to complete the procedure 
and complication of the procedure. 
RESULTS: 
One hundred and twenty (60 patients in 
each arm) patients were enrolled to the 
study.  The mean (SD) of the age 
[32.5(6.7) vs. 30.7(8.3) year, P = 0.102] 
and the number (%) of the nulliparae 
[38(63.3) vs. 32(53.3), P = 0.267] was not 
different between the two groups. There 
was no significant difference in the 
indications (infertility was the main 
indications), types of the operative 
hysteroscopic procedure (endometrial 
polypectomy and submucous 
myomectomy were the commonest) 
between the two groups, figure 1, 2.  
Compared with the controls, significantly 
more cervical dilatation was achieved in 
significantly shorter time in misoprostol 
group [42.30 (20.5) vs. 110.20 (25.3) sec, 
P< 0.001]. Consequently, the duration of 
the operative hysteroscopy was also 
significantly shorter in the misoprostol 
group (table 1). Likewise, significantly 
more patients [49(81.6%) vs 10(16.6%)] in 
misoprostol group the size 7 Hegar dilator 
was passed without use of force (table 1). 
In comparison with the controls; 
significantly fewer patients in misoprostol 
group had cervical lacerations [1 (1.6%) 
vs. 8 (13.3%), P < 0.001], creation of false 
passage during cervical dilatation [1 
(1.6%) vs. 4(6.6%), P < 0.001]. Four of the 
8 patients with cervical tear in the control 
group, required suturing.  There were two 
(3.3%) uterine perforations in the control 
group.  One occurred during cervical 
dilatation and one occurred during lysis of 
intrauterine adhesions (table 1). 
DISCUSSION: 
The main findings of the current study 
were; more cervical dilatation was 
achieved in significantly shorter time, 
operation time was shorter and the dilator 
was passed without force in misoprostol 
group.  This is goes with the previous 
studies that have shown that misoprostol     
administered     vaginally   was 
effective when compared with placebo for 
cervical ripening before diagnostic 
hysteroscopy and it reduced the pain score 
and facilitated easy entry of the 
hysteroscopy22,23. likewise it has been 
observed that even in operative 
hysteroscopy the use of misoprostol is 
beneficial6,20,24,25. Recently Gkrozou et al., 
in  their met-analyses confirmed that 
vaginal misoprostol significantly reduced 
the need for cervical dilatation and even in  
the operative hysteroscopy the need for 
dilatation and the duration of the operation  
were also significantly reduced26. Previous 
studies compared the vaginal misoprostol 
with placebo before operative 
hysteroscopy found that misoprostol  
Table (1):  the Outcome measures of the study 
The variable Misoprostol group  Control group P 
The mean  (SD)  of the     
  Cervical dilatation, mm  7.2 ( 0.5) 3.7 (1.5) < 0.001  
  Time for cervical dilatation to Hegar 10, sec  42.30 (20.5) 110.20 (25.3) < 0.001  
  Duration of operative hysteroscopy, min  37.2(10.2) 50.9 (14.6) < 0.001  
 Number (%)  of     
  Cervical dilatation to 7mm  49 (81.6) 10 (16.6) < 0.001  
  Cervical tear 1 (1.6) 8 (13.3) 0.015 
  Creation of a false passage 1 (1.6) 4 (6.6) 0.213 
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